Latest International Expansion News

archTIS Limited reported a 38% revenue decline and an 11.8% rise in net loss for FY2025, yet achieved positive operating cash flow and secured $7.5 million in new capital to accelerate international expansion.

Biome Australia Limited has reported its first net profit alongside a 41.6% jump in sales revenue, driven by strong domestic growth and expanding international partnerships.

SciDev Limited reported a 5% revenue decline in FY25 but secured major contracts and reaffirmed strong growth guidance for FY26. Key proprietary technologies like CatChek™ and PFAS treatment are driving expansion.

MyEco Group reported a 9% increase in FY25 sales driven by an 82% jump in MyEco branded products, alongside a strategic operational restructure aimed at cutting costs and boosting supply chain flexibility.

EBOS Group Limited reported solid FY25 results with 12% revenue growth and strategic acquisitions, setting sights on continued expansion and operational efficiency in FY26.

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

WhiteHawk Limited appoints Giuseppe Porcelli as Chief Strategy Officer to spearhead international growth and strengthen investor confidence, while progressing key U.S. federal cybersecurity contracts.

Chrysos Corporation reported a robust 46% revenue increase to A$66.1 million for FY25 but faced a significant net loss of A$8.2 million, reflecting rising costs and operational challenges.

SPC Global reports stronger-than-expected FY25 results driven by international growth and synergy gains, while unveiling a new premium beverage division and a major lender transition.

Noumi Limited reported a 13% rise in adjusted operating EBITDA for FY25, driven by strong growth in its plant-based milks and dairy segments. The company has resolved legacy litigation issues and is now focused on navigating the $610 million convertible note maturity due in 2027.

Noumi Limited reported modest revenue growth and a significant rise in adjusted EBITDA for FY25, driven by its Milklab brand’s strong performance and a continued turnaround in its Dairy & Nutritionals segment. The company also resolved all legacy legal issues, positioning itself for future growth.